What question did this study set out to answer?

To establish a standardized definition and validation framework for AI-based biomarkers in oncology.

April 10, 2026

ESMO publishes guidance on use of AI‐based biomarkers in oncology

Key Points

To establish a standardized definition and validation framework for AI-based biomarkers in oncology.
Review of current literature on AI tools in oncology
Discussion of regulatory approvals for AI-based systems
Analysis of treatment outcomes in breast cancer with T-DXd and carboplatin
Lack of a shared definition and validation standards for AI tools in oncology identified.
T-DXd demonstrated superior benefits over T-DM1 in early breast cancer patients.
Adding carboplatin to chemotherapy improved survival rates in early-stage triple-negative breast cancer.

Abstract

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, an ESMO guideline will address the fact that despite increasing interest in and regulatory approval of AI‐based tools in oncology, there has been no shared definition or validation standard for these systems. In addition, T‐DXd shows benefit over T‐DM1 in patients with early breast cancer, and adding carboplatin to adjuvant chemotherapy improved survival in early‐stage triple‐negative breast cancer.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Leah Lawrence

Journals

Cancer

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

ESMO publishes guidance on use of AI‐based biomarkers in oncology

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider